Quick Takeaways
- Novo Holdings A/S filed SCHEDULE 13G/A for 4D MOLECULAR THERAPEUTICS, INC. Common Stock, par value $0.0001 per share (FDMT).
- Disclosed ownership: 6.4%.
- Date of event: 31 Dec 2025.
Novo Holdings A/S - 31 Dec 2025 SCHEDULE 13G/A Report for 4D MOLECULAR THERAPEUTICS, INC. Common Stock, par value $0.0001 per share (FDMT)
- Filing Manager
- Novo Holdings A/S
- Reporting Manager
- Novo Holdings A/S
- Symbol
- FDMT
- Shares outstanding
- 57,042,766 shares
- Disclosed Ownership
- 3,650,737 shares
- Ownership
- 6.4%
- Form type
- SCHEDULE 13G/A
- Filing time
- 17 Feb 2026, 18:55:37 UTC
- Date of event
- 31 Dec 2025
- Previous filing
- 20 Oct 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Novo Holdings A/S disclosed 6.4% ownership in 4D MOLECULAR THERAPEUTICS, INC. Common Stock, par value $0.0001 per share (FDMT) on 31 Dec 2025."
What Changed
- Previous schedule filing date: 20 Oct 2025.
- Current filing was accepted on 17 Feb 2026, 18:55.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Novo Holdings A/S | 6.4% | 3,650,737 | 3,650,737 | 0 | Barbara Fiorini | Barbara Fiorini, General Counsel, Finance & Operations |